Vasigar Prathap, Batmanabane Mounissamy
Department of Anatomy, Sri Manakula Vinayagar Medical College and Hospital, Puducherry, India.
J Pharmacol Pharmacother. 2013 Oct;4(4):238-42. doi: 10.4103/0976-500X.119707.
To evaluate the anti-inflammatory effect of the third-generation CCB, lercanidipine.
The ability of lercanidipine to reduce inflammation in carrageenan-induced paw edema in rats was evaluated, using different doses and its anti-inflammatory effect was compared with that of diclofenac sodium. Mast cell degranulation effect of lercanidipine was also carried out.
Lercanidipine produced a significant reduction in the inflammatory paw edema at all doses and at all intervals (P < 0.001). The percentage of reduction in edema was found to be proportionate to the doses of lercanidipine. Lercanidipine also significantly reduced the percentage of propranolol-induced mast cell degranulation.
It was found that lercanidipine exerts a positive anti-inflammatory effect in a dose-dependent manner and was superior to diclofenac sodium.
评估第三代钙通道阻滞剂乐卡地平的抗炎作用。
评估乐卡地平对大鼠角叉菜胶诱导的爪肿胀的抗炎能力，采用不同剂量，并将其抗炎效果与双氯芬酸钠进行比较。同时也进行了乐卡地平对肥大细胞脱颗粒作用的研究。
所有剂量和所有时间间隔下，乐卡地平均能显著减轻炎性爪肿胀（P < 0.001）。发现水肿减轻的百分比与乐卡地平的剂量成比例。乐卡地平还显著降低了普萘洛尔诱导的肥大细胞脱颗粒百分比。
发现乐卡地平以剂量依赖方式发挥积极的抗炎作用，且优于双氯芬酸钠。
